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Abstract
We introduce a stochastic model describing aggregation of mis-
folded proteins and degradation by the protein quality control system
in a single cell. In analogy with existing literature, aggregates can
grow, nucleate and fragment stochastically. We assume that the qual-
ity control system acts as an enzyme that can degrade aggregates at
1
different stages of the growth process, with an efficiency that decreases
with the size of the aggregate. We show how this stochastic dynamics,
depending on the parameter choice, leads to two qualitatively differ-
ent behaviors: a homeostatic state, where the quality control system
is stable and aggregates of large sizes are not formed, and an os-
cillatory state, where the quality control system periodically breaks
down, allowing for the formation of large aggregates. We discuss how
these periodic breakdowns may constitute a mechanism for the spo-
radic development of neurodegenerative diseases. Key words: protein
aggregation — Neurodegenerative diseases — stochastic dynamics —
spiky oscillations — proteasome — lysosome
1 Introduction
Protein aggregation and formation of amyloid fibrils have been a subject
of intense experimental and theoretical study in recent years. The main
motivation has been that protein aggregation, including the formation of
cytotoxic pre-amyloid species and larger inclusion bodies, seems to be the
common theme underlying most known neurodegenerative diseases (1, 2).
Besides structural studies, several attempts have been made to build up
coarse-grained models, able to characterise the aggregation process from a
kinetic point of view without any influence of a cellular environment. One
of the key features which are needed in the description is the existence of
a nucleation mechanism (3). During the late stages of the aggregation, the
possibility of aggregates to break into smaller fragments also becomes impor-
tant (4,5). Several other models have later been introduced, including more
detailed mechanisms (6–8).
While amyloid growth and aggregation in vitro is quite well character-
ized nowadays, much less is known about the corresponding phenomenon in
vivo. This is the main focus in this paper. The in vivo case is of crucial
relevance since a common theme of many neurological disorders is undesired
intercellular protein aggregation, and insights would be thus helpful to the
understanding of disease development as well as treatments.
Apart from the experimental limitations, the in vivo case presents also
a number of theoretical challenges. Accepting as a working hypothesis that
the development of neurological disorders is directly associated with the ag-
gregation process, it is unclear why such diseases develop in a time frame of
several years, while in vitro aggregates can typically grow on timescales of
2
hours or days. Another ubiquitous feature of neurological disorder is their
sporadic development: degeneration is not gradual but occurs in almost-
discrete steps. While a similar dynamical behaviour has been observed in
vitro (9, 10), also in this case there is a large gap between the timescales
observed in experiments and those characterizing the disease.
We examine the dynamics of in vivo aggregation where the cell’s quality
control system tries to prevent protein aggregation by acting at different
stages of the growth process. For example, in the case of Parkinson disease,
it has been observed how α-synuclein can be degraded both by the ubiquitin-
proteasome system (UPS) and by autophagy (11). The possibility of such
mechanisms to degrade aggregates of α-synuclein is currently under debate.
In a previous study, we explored the consequences of the interaction be-
tween α-synuclein and the UPS system (12). We found that such system
displays a transition between a state in which the UPS system can effec-
tively prevent aggregation, and one in which spiky oscillations are observed.
During such spikes, the UPS is impaired, allowing for growth of aggregates.
However, the model we considered lacked a description of the aggregation
kinetics.
To address this issue, we study a model describing the behaviour of the
battle between protein aggregation and the quality control system in a single
cell. We implement the aggregation process in a similar way as in (7): aggre-
gates are formed when a nucleation threshold is passed, and grow according
to the existing concentration of monomers. Further, large aggregates can
break into smaller fragments. To this mechanism, we couple the response of
the protein quality control system. We assume that its action can be mod-
eled as an enzymatic degradation, whose efficiency depends on the size of
the aggregate. We mostly identify this system with the UPS, as it is bet-
ter characterized from a biochemical point of view than other systems such
as lysosomes. However, larger fragments are more likely to be attacked by
autophagy, whose possible effect we will also discuss.
In order to assess the effect of intrinsic noise on the resulting dynamics, we
have implemented all reactions stochastically using the Gillespie algorithm
(16). We observe that, even in the presence of stochasticity, aggregation in
this model is not continuous, but occurs in fairly regular spikes. During these
spikes, aggregates of all sizes can quickly be formed. Such spikes become more
irregular if the degrading agent is present on average in low numbers in the
cell. Before discussing the consequences of our findings, we outline the details
of our model.
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Figure 1: Total set of reactions that defines our model of protein aggregation
(top panel) and subsequent degradation by the cell’s quality control system
(bottom right panel). The quality-control system is under cellular regulation
(bottom left panel).
2 Model
Our model describes the stochastic growth of fibrillar aggregates during con-
stant attack by the cell’s protein quality-control system. We define fn as the
number of free aggregates made up of n monomers present in the cell, so that
f1 is the number of free monomers, or aggregation-prone proteins. We will
assume that the action of the quality control system can be modelled as an
enzymatic degradation, where we have the case of the UPS response system
as an example in mind. The number of free degradation enzymes available in
the cell is denoted by E. Such enzymes can degrade fibrils of size n through
the formation of a long lived complex Cn. The interplay between fn, E and
Cn is summarised in Fig. (1) and discussed below.
In analogy with existing models (4,7) we describe the dynamics of aggre-
gate formation in terms of two basic processes (top panel in Fig. 1): (R1)
step-wise growth by attachment of monomers to one of the fibril ends, and
(R2) random breakage of aggregates into smaller fragments. Reactions (R1)
and (R2) occur at rates γ and β, respectively. In addition to (R1) there is
a possibility to introduce a nucleation barrier so that the reaction in which
two monomers bind (R1’) f1+f1
γ′
−→ f2 is slower than (R1), i.e. γ
′ ≪ γ. The
dynamics of (R1) and (R2) have been shown to be consistent with results
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of in vitro aggregation experiments (7). In addition to (R1) and (R2), we
consider a constant production of monomers at rate µ (R3).
The cell’s protein quality-control system, here represented by a generic
degradation enzyme E, attacks fibrillar aggregates of all sizes in order to
keep their concentration at a low level. The enzyme is produced at rate α
(R4) and each molecule is degraded with rate δ (R5) (bottom left panel).
The steady-state concentration of E in absence of fibrils is then α/δ.
The degradation of aggregates by the degradation enzyme is assumed to
take place as a two-step process (bottom right panel). First, it binds to fibrils
of a given size n and forms a complex Cn (R6). Then, in a time proportional
to n, the aggregate is entirely degraded and the enzyme is released and ready
to deal with another aggregate (R7). In general, it is unreasonable to assume
that the degradation capability of the quality control is simply inversely
proportional to n. A more realistic assumption would be to let η and ν
have a non-trivial size dependence. The functions η(n) and ν(n) may be also
different for different agents, describing the spectrum of aggregates that each
of them can effectively bind and degrade. For example, a proteasome could
be able to attack misfolded monomers and eventually early stage aggregates,
while lysosomes might effectively attack larger bodies. However, given the
poor biochemical characterisation of these agents, we consider only one of
them at a time and keep η and ν independent of n. However, to avoid
the possibility of the enzyme to attack unreasonably large aggregates, we
introduce an upper limit nmax to the aggregate size that the proteasome can
bind to.
In summary, our model is defined by reactions (R1)-(R7) with ingoing
parameters γ(γ′), β, µ, α, δ, η, ν and nmax.
3 Results
We investigated the dynamics of the model introduced in the previous section
using computer simulations. In order to include properly the effects caused
by intrinsic noise, we implemented all the reactions stochastichally via the
Gillespie algorithm (16). Parameters were selected according to physiologi-
cal conditions based on measured aggregation rates of proteasomal dynamics.
The one exception is α which is left as a free parameter in our model. Since
we are interested in the long-time behaviour, all time units are in days. Reac-
tions rates are therefore expressed in [day]−1, [day]−1 per molecule or [day]−1
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per couple of molecules, depending on reaction order (number of chemical
species on the reaction’s left-hand side). We will start our analysis by iden-
tifying the enzyme with the ubiquitin-proteasome system, which we refer to
simply as the proteasome, the main reason being that it is biochemically well
characterised (compared to e.g. lysosomes).
The parameters characterizing the aggregating monomers have been cho-
sen having α-synuclein in mind as example. However, the model can be easily
adapted to describe aggregation of other proteins. We fix the parameters ac-
cording to this choice and later vary key parameters in order to probe the
different behaviours of the model. The specific choice of all numerical values
of the parameters is discussed in Appendix 6.
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Figure 2: Homeostatic state. (left) Number of molecules as a function of
time (right) size distribution of bound aggregates. The following parameters
were used: γ = 2 · 10−5, γ′ = 2 · 10−10, β = 10−3, nmax = 10
6, µ = 6 · 104,
α = 102, δ = 0.1, η = 0.02, ν = 102. All rates are in unit [day]−1, [day]−1
per molecule or [day]−1 per couple of molecules, depending on the order of
the reaction.
Figure 2 shows the dynamics of the model with the parameter choice from
Appendix 6 without any alteration. The result is a stationary homeostatic
state, after a short period of transient behaviour from the initial conditions,
where there is a chemical balance between proteasome concentration and the
formation of aggregates. The proteasome is in the model denoted E whereas
filaments and bound filaments represent a sum over all sizes excluding the
free monomers f1, that is
∑
n>1 fn and
∑
nCn. The figure shows that their
concentrations fluctuate moderately around well defined average values which
means that the proteasome is fully functioning and keeps the total aggregate
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concentration down. In this homeostatic state there is also a fast decay (well
fitted by an exponential) of the aggregate size distribution as a function of n
(right panel) as well as bound fibrils (Cn) (not shown).
Coupled kinetic equations for the aggregation process (R1)-(R2) with
a finite pool of monomers were solved analytically in (7). The model we
consider here is more complicated due to the non-linear coupling with the
proteasome and does therefore not lend itself easily to analytical treatments.
The problem does however simplify if we let the aggregate size n be a con-
tinuous variable. Indeed, one can show (see Appendix 7) that the aggregate
size-distribution in the homeostatic case decays exponentially with n. This
means that very large fibrillar aggregates are unlikely to be formed in this
regime; as a consequence, the value of nmax is irrelevant, as soon as it is
reasonably large. This contrasts the behaviour of the model in the absence
of any proteasome degradation where fibrils grow at a much higher rate, up
to a size which is essentially unlimited. An unlimited growth that in in vitro
experiments becomes limited by the available pool of aggregating peptide
chains (7).
102
104
106
108
1010
2 102 4 102 6 102 8 102 1 103
pr
ot
ei
n 
nu
m
be
rs
t
Oscillatory state
proteasome
filaments
monomers
complex
Filament size spectrum
 2 102  4 102  6 102  8 102  1 103
t
 20
 40
 60
 80
 100
Fi
la
m
en
t s
iz
e
 1
 10
 100
 1000
 10000
Figure 3: Oscillatory state, number of molecules as a function of time. Pa-
rameters are same as Fig. 2 but µ is 5 times larger, µ = 3 · 105. (left)
number of molecules as a function of time, (right) size distribution of bound
aggregates.
If the monomer production rate (µ) is increased, homeostasis breaks down
and oscillations emerge (Fig. 3, left panel). In this regime there are dramatic
drops in proteasome concentration which stays low for long periods of time,
leading to a buildup of larger and larger fibrillar aggregates. The quality
control system cannot in this case cope with the amount of aggregates present
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in the system which results in a non-exponential decay in the aggregate size
distribution with n. The distribution becomes heavy tailed, and aggregates
may reach sizes larger than nmax, i.e. large enough to escape the repair
system.
The striking outcome of the model is that destabilisation of the quality
control system is episodic. The system alternates between states in which
the quality control system is functioning, and short periods in which the
proteasome is impaired. During such periods, aggregates of all sizes are pre-
dicted, as shown in the right panel of Fig. 3. This is a consequence of the
fact that the growth dynamics, in the absence of the proteasome, is faster
than the timescale of the recovery of the quality control system. The largest
aggregates size that the proteasome can attack is controlled by nmax and
if aggregates larger than nmax are formed, nothing can prevent such aggre-
gates from reaching very large sizes, even when the quality control system
has recovered. Finally, despite the fact that simulations are stochastic, the
period of the oscillations is remarkably regular. This is a consequence of the
(average) high copy number of all proteins involved.
We also remark that, starting from the homeostatic state of Fig. 2, the
onset of oscillations can be triggered by varying different parameters. In par-
ticular, reducing the proteasome production rate α, and/or the proteasome
degradation efficiency ν trigger oscillations.
3.1 Lysosomal degradation
Autophagy is the process by which cytosolic membrane-bound compartments
engulf substrates, such as mis-folded proteins or protein aggregates, that ul-
timately fuse with the lysosome for degradation of their content (19). For ex-
ample, mis-folded α-synuclein protein in Parkinson’s disease has been identi-
fied as substrate for this type of autophagy (11). Autophagy can be regarded
as a back-up system to complement proteasomal degradation when it is over-
whelmed or incapable of dealing with specific aggregated substrates. Indeed,
experiments strongly suggest that the removal of mis-folded proteins through
autophagy and the ubiquitin proteasome system are interconnected (20), as
impairment of the ubiquitin proteasome system induces compensatory au-
tophagy.
This type of protein degradation is not so well characterised biochemically
compared to for instance proteasomal degradation. But in order to test
the effect of autophagic-like degradation we tuned our model parameters to
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Figure 4: Oscillations in the presence of lysosome. Parameters are: γ =
2 · 10−5,γ′ = 2 · 10−10, β = 10−3, nmax = 10
6, µ = 6 · 104, α = 1,δ = 0.1,
η = 0.02, ν = 104. The only parameters that differ from the case of Fig.
2 are α and ν. As usual, (left) number of molecules as a function of time,
(right) size distribution of filaments. Notice how oscillations are much more
stochastic as a consequence of the presence of small numbers of lysosomes.
represent the lysosome as an efficient enzyme present only in small copy
numbers. We assumed a production rate α = 1 lysosome per day, and a
degradation rate of δ = 0.1 lysosomes per day which corresponds to an
average of 10 lysosomes per cell at steady state. We assumed furthermore
that the rate at which the enzyme degrades aggregates (per aggregate size) is
ν = 104, which is a hundred times more efficient than the proteasome. Other
mechanisms may be introduced to describe lysosomal dynamics in a more
realistic ways. For example, one could introduce the possibility to deal with
multiple aggregates at the same time, or a processing time having a different
dependence on the n. For simplicity, we do not explore such possibilities
here.
Figure 4 shows the results of a simulation for our new parameter choice.
Even in this case we observe oscillations: the reason is that the higher effi-
ciency is compensated by the lower numbers. The main difference between
this case and that in fig. 3 is that the period of the oscillations is much
more stochastic. This is a consequence of the enzyme being present in small
numbers and the breakdown of the protein quality control system is much
less regular in this case.
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4 Discussion
In this paper we have studied the interplay between sequential growth of
amyloid fibrils and its degradation by the quality control system in a single
cell. Our model exhibit two types of dynamical behaviours. For one set of
parameters the number of molecules is stationary and fluctuate around a well
defined constant mean, while for the complementary set the system oscillates.
These features were also captured in a simplified deterministic model (12)
where the incremental fibrillar growth was replaced by a two-step process
(small and large aggregates). However, the present study demonstrates how
the dynamical behaviour observed in (12) is present also in a more mecha-
nistic model, where the aggregation process is taken explicitly into account.
Further, we demonstrate how such transition can occur for parameters values,
to the best of our knowledge, under physiological conditions.
The main result of the model is that, in the regime in which the quality
control system can not cope with the amount of fibrils, destabilisation of
the homeostatic state gives rise to an oscillatory regime. Such oscillations
are characterised by long time lapses in which the quality control system is
functioning and prevents aggregation, separated by shorter lapses of time
in which the quality control system is impaired and fibrils of large sizes
can grow. The period of such oscillations depends on the parameter choice
but is typically on the scale of months, thus predicting a slow and stepwise
formation of large aggregates. Such phenomenology is reminiscent of the
remarkably slow and sporadic development of neurodegenerative diseases.
Finally, we have shown that when the agent degrading the aggregates is
present in large numbers, the resulting oscillations tend to be very regular
and almost deterministic, while when the numbers are smaller oscillations
are more stochastic.
There are clearly a number of generalisations one can consider to account
for more accurate experimental evidences, such as the possibility of different
interconnected repair systems, that attack aggregates at different stages of
the growth process and with different efficiencies depending on the aggre-
gate size. Our model should be considered as a minimal mechanistic model
displaying such non-trivial phenomenology.
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6 Appendix: choice of parameters
In this appendix, we discuss our initial choice of parameters. We start the
discussion with the parameters characterizing the aggregation/fragmentation
part of the model. Studies on insulin (13) reported fibril growth rates around
0.3 monomers per fibril per second in the presence of a monomer concen-
tration of 0.17 mM . Similar studies on other molecules (14) report sim-
ilar values. The average diameter of a dopaminergic neuron is from 10
to 20µm (see e.g. (15)). This will give a cell volume around v = 10−11l.
One single monomer in the cell will then correspond to a concentration of
1/(NAv) ≈ 2 · 10
−13M where NA is the Avogadro number. The growth rate
per fibril per monomer will then be 0.25 · 10−9s−1, that is approximately
2 · 10−5 monomers per fibril per day. In Ref. (13) it is estimated from reac-
tion rate arguments that one every 105 encounter events between filaments
and monomer result in attachment.
Fitting models on aggregation to experiments suggest that the nucleation
barrier can lead to an activation rate being 8-9 orders of magnitudes smaller
than the growth rate after nucleation (7). This rate could however be different
in vivo, since cell condition can significantly alter the nucleation barrier and
favour/disfavour the formation of nucleation seeds. We choose a relatively
high nucleation rate (compared with in vitro experiments), γ′ = 2 · 10−10.
We fixed a filament breakage rate β = 10−3 (7). We observed that varying
this rate has little effect on the outcome of the model, as most filaments are
actively degraded by the quality control system. We also fixed nmax = 10
6;
also this last parameter do not change the qualitative dynamics of the system
when it is large enough, as the distribution of fibrils decays exponentially with
their size in the stable regime. However, lowering the value will increase the
chance that an aggregate may grow large enough to escape degradation to
the quality control system. The production rate of monomers α is left as a
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free parameters. Since its value is typically large, to speed up the simulations
we implemented an alternative reaction in which 100 monomers at a time are
produced with a rate α/100. We checked in shorter simulations that such
approximation does not alter significatively the results, thanks to the typical
high numbers of monomers.
We move now to the parameters related to the proteasome. Proteasome
lifetime is estimated to be 8-15 days in the cell (17, 18), leading to a degra-
dation rate δ = 0.1. The proteasome production rate α is left as a free pa-
rameter. On general grounds, we may expect the proteasome to bind better
to the filaments than to a monomer, leading to a complex formation η being
larger than γ. We pick η = 0.02, corresponding to one successful binding
event every 100 encounters. A lower value of η would make the proteasome
less effective and would simply result in a higher threshold value for α to
observe oscillations, without affecting the qualitative features of the model.
Finally, the degradation rate of individual molecules by the proteasome is
estimated to be on the order of minutes, so we pick ν = 103.
7 Appendix: continuous limit
If we treat the number of number of monomers n forming an aggregate as
a continuous variable, our model can be treated analytically. Adopting the
notation from Fig. 1 the governing equations for the molecular concentrations
are
∂fn(t)
∂t
= −γ
∂fn(t)
∂n
− ηfn(t)E(t), (1)
∂Cn(t)
∂t
= ηfn(t)E(t)−
ν
n
Cn(t), (2)
∂E(t)
∂t
= 1−E(t) +
∫ nmax
1
dn
(
ηfn(t)E(t)−
ν
n
Cn(t)
)
, (3)
Here we neglected filament breakage (β = 0) and n ≥ 1. We have also
rescaled enzymatic growth and degradation rates as well as the filament
length n to 1. The constant production of monomers enters as the boundary
condition
−
(
∂fn(t)
∂n
)
n=1
= µ. (4)
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In the homeostatic ”healthy” state it is straightforward to show that the
time independent stationary (ST) concentrations are given by
fSTn (n) =
µγ
η
e−η(n−1)/γ , CSTn (n) =
nγµ
µ
νe−η(n−1)/γ , P ST = 1, (5)
which shows that the size distribution of filaments fSTn decays exponentially.
Moreover, the complex concentration CSTn grows with n until it reaches a
maximum at n¯ = η/γ after which it also decays exponentially.
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